Status:
RECRUITING
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Sickle Cell Disease
Sickle Beta Zero Thalassemia
Eligibility:
All Genders
12-21 years
Phase:
NA
Brief Summary
The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test th...
Detailed Description
Sickle cell disease is the most common genetic disorder in the US, affecting about 100,000 Americans, and about 1 in 400 African American live births, incurring annual health care costs of $335 millio...
Eligibility Criteria
Inclusion
- Age 12-21 years old
- Any sickle cell disease genotype
- On steady state of hydroxyurea for 2 months
- Own of have access to a smartphone during the study period
Exclusion
- Recent hospitalizations within the past 7 days
Key Trial Info
Start Date :
September 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04688411
Start Date
September 28 2020
End Date
February 1 2025
Last Update
November 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611